The FDA has awarded Roche an accelerated review of its immunotherapy drug, Tecentriq, to treat non small-cell lung cancer.
Tecentriq was given priority review as a treatment mixed with chemotherapy. In September, Roche announced results from a study showing that patients receiving Tecentriq in combination with chemotherapy lived a median of 12.3 months, compared to 10.3 months with chemo alone.
In the market for immuno-oncology drugs, Roche has been lagging behind competition from Mercky’s Keytruda and Bristol Myers Squibb’s Opdivo, which have already been approved for several indications. But with the latest FDA nod, Roche said that Tecentriq could be approved for the lucrative market for non small-cell lung cancer by March 18.
Tecentriq is already being used to treat later-stage lung and bladder cancers.
Read the full Reuters report.
[javascriptSnippet]